Cortex Pharmaceuticals - History

History

February 2005 – Cortex received U.S. Food and Drug Administration approval to begin Phase II clinical trials for CX717 for use as a treatment for Alzheimer’s, ADHD and Sleep disorders.
2006 – The FDA halted clinical trials for CX717 because they feared the drug was toxic. They later allowed testing to continue but at doses too low to have any effect.
July 2007 – The FDA gave Cortex permission to continue with clinical trials for CX717, as a treatment for Alzheimer's disease.
September 2007 – Cortex filed with the FDA to test CX717 as a treatment for ADHD.
October 2007 – Dr. Pierre Tran became Chief Medical Officer at Cortex after the FDA refused to let the company proceed with Phase II clinical trials for CX717 as a treatment for ADHD.
March 2008 – German regulators approved clinical studies for using CX717 to prevent breathing problems caused by opiate pain-killers. May 2008 – President and CEO Dr. Roger Stoll announced that he was resigning and would be replaced by Mark Varney.

Read more about this topic:  Cortex Pharmaceuticals

Famous quotes containing the word history:

    The only thing worse than a liar is a liar that’s also a hypocrite!
    There are only two great currents in the history of mankind: the baseness which makes conservatives and the envy which makes revolutionaries.
    Edmond De Goncourt (1822–1896)

    Perhaps universal history is the history of the diverse intonation of some metaphors.
    Jorge Luis Borges (1899–1986)

    We said that the history of mankind depicts man; in the same way one can maintain that the history of science is science itself.
    Johann Wolfgang Von Goethe (1749–1832)